Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.
